Epoetin Alfa and Darbepoetin Alfa Go Head to Head

This publication has 24 references indexed in Scilit:

• Randomized Comparison of Every-2-Week Darbepoetin Alfa and Weekly Epoetin Alfa for the Treatment of Chemotherapy-Induced Anemia: The 20030125 Study Group Trial
  Journal of Clinical Oncology, 2006
• Benefits Associated with an Early Hemoglobin Response to Epoetin Alfa Therapy in the Treatment of Chemotherapy-Related Anemia
  Journal of the National Comprehensive Cancer Network, 2005
• The anaemia of cancer: death by a thousand cuts
  Nature Reviews Cancer, 2005
• Phase III, Randomized, Double-Blind Study of Epoetin Alfa Compared With Placebo in Anemic Patients Receiving Chemotherapy
  Journal of Clinical Oncology, 2005
• Management of anemia in patients with cancer
  Current Oncology Reports, 2004
• A multicenter retrospective cohort study of practice patterns and clinical outcomes of the use of darbepoetin alfa and epoetin alfa for chemotherapy-induced anemia
  Clinical Therapeutics, 2003
• Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial
  The Lancet, 2003
• Breast cancer trial with erythropoietin terminated unexpectedly
  The Lancet Oncology, 2003
• Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy
  British Journal of Cancer, 2002
• Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group.
  Journal of Clinical Oncology, 1997